Krebs Biochemicals & Industries Ltd. (KREBSBIO) AI Stock Analysis

• Market Cap: ₹1.06B
• Dividend Yield: N/A
• Average Volume (3M): 726.00
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -46.31%
• EPS Growth: -26.28%
• Country: IN
• Employees: 191
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -1.45
• Shares Outstanding: 21,560,587
• 10 Day Avg. Volume: 346
• 30 Day Avg. Volume: 726
• PEG Ratio: -0.15
• Price to Book (P/B): -1.00
• Price to Sales (P/S): 3.37
• P/FCF Ratio: -12.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: ₹48.00 ▼(-32.39% Downside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is driven primarily by very weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals also lean bearish with the price below major moving averages and negative MACD. Valuation provides limited support because the company is loss-making and offers no dividend yield.

Positive Factors

B2B biochemical manufacturing model

A B2B supply model to industrial buyers creates more predictable, contract-driven demand versus consumer markets. Over months the company can rely on recurring orders and long-term customer relationships, supporting revenue stability if operations and pricing normalize.

Niche specialty/generic chemical focus

Specialization in biochemical inputs for specialty and generic drug sectors implies technical know-how and niche product demand. Structural pharmaceutical and specialty chemical needs can sustain long-term orders and create higher switching costs for industrial customers.

Positive EPS growth trend

Reported EPS growth despite large revenue declines suggests operational leverage or capital structure effects that have improved per-share results. If sustained, this indicates management can extract more profit per share as revenue recovers, aiding long-term recovery options.

Negative Factors

Persistent negative profitability

Sustained negative net income and EBIT margins degrade the company's ability to fund operations, invest, or compete. Over months this erodes retained capital, complicates supplier/customer confidence, and constrains strategic initiatives needed for durable turnaround.

Chronic negative operating and free cash flow

Ongoing negative operating and free cash flow means the business does not generate internal cash to sustain working capital or capex. This necessitates external financing, increasing vulnerability to credit conditions and limiting the firm's ability to stabilize operations long-term.

Highly leveraged balance sheet and negative equity

Negative shareholder equity and high leverage raise insolvency risk and restrict access to affordable capital. Over a multi-month horizon this limits strategic flexibility, may force asset sales or restructuring, and undermines resilience to industry or input-cost shocks.

Krebs Biochemicals & Industries Ltd. Business Overview & Revenue Model

Company Description

Krebs Biochemicals & Industries Limited manufactures and sells active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry fields. Its products, such as androstenedione, lovastatin, and simvastatin for anti-cholesterol and steroid intermediate applications. The company is also developing various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. Krebs Biochemicals & Industries Limited was incorporated in 1991 and is headquartered in Hyderabad, India.

How the Company Makes Money

The company primarily makes money through the sale of its manufactured biochemical/chemical products to customers (typically industrial buyers) under B2B supply arrangements. Revenue is generated from product sales volumes multiplied by realized selling prices, with profitability influenced by manufacturing utilization, input/raw-material costs, energy costs, and product mix. null

Krebs Biochemicals & Industries Ltd. Financial Statement Overview

Summary

Financial statements indicate severe weakness: persistent losses with materially negative net income/EBIT margins, declining revenue, negative equity and high leverage risk, and consistently negative operating and free cash flow that pressures liquidity and solvency.

Income Statement

Krebs Biochemicals & Industries Ltd. has consistently faced challenges in generating profits, with negative net income and EBIT margins over multiple years. The net profit margin and EBIT margin are significantly negative, indicating ongoing operational difficulties. Revenue has been declining, and the gross profit margin is also poor, highlighting inefficiencies in cost management and sales performance.

Balance Sheet

The balance sheet reveals a highly leveraged position with a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is unfavorable due to the high level of debt relative to equity, and the equity ratio is negative, underscoring the company's risk of insolvency. This presents a significant risk for creditors and investors.

Cash Flow

Krebs Biochemicals & Industries Ltd. has struggled with cash flow management, as evidenced by negative free cash flow and operating cash flow across multiple years. The free cash flow to net income ratio is poor, indicating that the company is not effectively converting its earnings into cash. This ongoing cash flow issue poses a challenge for sustaining operations and meeting financial obligations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	272.16M	433.12M	504.21M	521.34M	597.03M	386.06M
Gross Profit	207.34M	377.56M	-108.75M	244.19M	-57.64M	-136.26M
EBITDA	-143.95M	-143.21M	-82.73M	-151.62M	-328.46M	-169.63M
Net Income	-274.74M	-269.39M	-197.28M	-246.92M	-445.27M	-283.59M
Balance Sheet
Total Assets	1.68B	1.69B	1.78B	1.75B	1.90B	1.59B
Cash, Cash Equivalents and Short-Term Investments	1.27M	3.38M	1.37M	858.00K	1.01M	7.11M
Total Debt	2.19B	2.12B	2.39B	1.83B	1.88B	1.11B
Total Liabilities	3.26B	3.15B	2.97B	2.74B	2.65B	2.02B
Stockholders Equity	-1.58B	-1.46B	-1.19B	-994.62M	-750.93M	-427.33M
Cash Flow
Free Cash Flow	-37.27M	-114.54M	-70.50M	-355.84M	-407.36M	-400.81M
Operating Cash Flow	-16.76M	-78.91M	23.65M	-247.13M	-172.16M	-145.75M
Investing Cash Flow	-21.83M	-49.70M	-78.17M	-126.45M	-229.00M	-225.49M
Financing Cash Flow	38.44M	128.65M	55.64M	373.43M	395.06M	376.61M

Krebs Biochemicals & Industries Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 71.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KREBSBIO, the sentiment is Negative. The current price of 71 is above the 20-day moving average (MA) of 54.52, above the 50-day MA of 58.23, and below the 200-day MA of 71.12, indicating a bearish trend. The MACD of -2.56 indicates Positive momentum. The RSI at 35.85 is Neutral, neither overbought nor oversold. The STOCH value of 9.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KREBSBIO.

Krebs Biochemicals & Industries Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	60 Neutral	₹1.27B	21.48	―	―	14.53%	-10.49%
BAFNAPH	58 Neutral	₹2.82B	48.53	―	―	-0.77%	2055.99%
BALPHARMA	58 Neutral	₹1.08B	16.40	―	1.62%	-9.07%	5.36%
VAISHALI	54 Neutral	₹641.01M	21.33	―	―	18.35%	-154.65%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAREYDRUGS	48 Neutral	₹1.91B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	41 Neutral	₹1.06B	-11.90	―	―	-46.31%	-26.28%

Krebs Biochemicals & Industries Ltd. Corporate Events

Krebs Biochemicals Board Clears Q3 FY2025 Unaudited Results After Clean Review

Krebs Biochemicals & Industries Ltd. announced that its board of directors has approved the unaudited financial results for the third quarter and nine-month period ended 31 December 2025, fulfilling its disclosure obligations to stock exchanges. The board meeting, held on 9 February 2026, also noted the auditors’ limited review report on these standalone results, confirming that no material misstatements or non-compliance with Indian Accounting Standards and listing requirements were identified.

The completion of this review process signals continued regulatory compliance and financial reporting discipline, providing investors and other stakeholders with interim visibility into the company’s performance. While specific financial figures were not disclosed in the announcement, the clean limited review report supports confidence in the reliability of the disclosed numbers and underscores the company’s adherence to governance norms in the Indian capital markets.

Krebs Biochemicals to Shut Trading Window Ahead of Q3 Results

Krebs Biochemicals & Industries Ltd. has announced that, in line with SEBI (Prohibition of Insider Trading) Regulations, 2015, it will close its trading window for dealings in its securities from the close of business on 31 December 2025 until 48 hours after the declaration of its unaudited financial results for the third quarter and nine months ended 31 December 2025. The restriction applies to promoters, directors, designated persons, their immediate relatives and other connected parties, and signals the company’s preparation for its upcoming financial disclosure, with the exact date of the board meeting to consider these results to be communicated to the exchanges in due course.